All Videos

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss differences between biosimilars and reference products.

Roy M. Fleischmann, MD and Joel M. Gelfand, MD, MSCE, FAAD define the terms biologic and biosimilars and discuss how they are developed.

Expert dermatologist, Susan Taylor, MD, FAAD, discusses available sunscreen options to patients.

Susan Taylor, MD, FAAD, discusses FDA regulations for sunscreens.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks about how to improve wrinkles fast.

Drs Noor and Lamb highlight the importance of frank discussion of adverse effects of atopic dermatitis treatments with patients.

Drs Bhatia, Lamb and Noor talk about the importance of building trust with patients and highlight topics to discuss with patients and parents.

Susan Taylor, MD, FAAD, addresses gaps in understanding damage to the skin by the general population.

Expert dermatologist Susan Taylor, MD, FAAD, provides education to community dermatologists about the pathophysiology of skin damage

Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.

Results published in the Journal of the American Medical Association (JAMA) Dermatology detailed the efficacy and safety of berdazimer gel 10.3%, in the treatment of molluscum contagiosum.

Dermatology experts discuss strategies to increase awareness of advances in AD in patients with SOC.

Drs. Neal Bhatia and Angela Lamb provide an overview of atopic dermatitis and its prevalence in patients with skin of color (SOC).

In this week’s Pointers with Dr Portela, the 208SkinDoc talks about how to overcome hormonal acne and other skin care tips.

Susan Taylor, MD, FAAD, compares how skin damage can occur in individuals with skin of color compared with individuals with light skin.

Susan Taylor, MD, FAAD, provides an overview of sun-caused skin damage.

At the SPD 2022 47th Annual Meeting, we chat with Albert Yan, MD, of Children's Hospital of Philadelphia on the latest trends in technology for pediatric dermatologists.

At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.

At the SPD 2022 47th Annual Meeting, a poster session looks at the updated guidelines for rosacea, and whether they are inclusive of children.

At the SPD 2022 47th Annual Meeting, a recap of don’t-miss sessions for Sunday, July 10.

Amy Paller, MD, shares key takeaways from her session at the SPD 2022 47th Annual Meeting in Indianapolis.

At the SPD 2022 47th annual meeting, investigators share data on the treatment of ruxolitinib for this chronic autoimmune disease.

At the SPD 2022 47th Annual Meeting, researchers delve into the safety and practicality of using narrow-band UVB phototherapy on children with vitiligo.

At the SPD 2022 47th Annual Meeting, a discussion of the latest therapeutics for acne.

At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, Candrice Heath shares her takeaways "Atopic dermatitis in skin of color."

At the SPD 2022 47th Annual Meeting, a discussion of habitual skin and hair disorders in children and adolescents.

At the SPD 2022 47th Annual Meeting in Indianapolis, Candrice R. Heath, MD, FAAP, FAAD shares compelling best practices for treating patients of color with this condition.

Bernard A. Cohen, MD, shares what he thinks will be most exciting at this year's Society for Pediatric Dermatology Meeting in Indianapolis, Indiana.

Recent advances in technology have begun to allow the realization of personalized medicine in the practice of dermatology.